NTU Develops Novel 2-in-1 Biomarker and Drug Delivery System
Nanyang Technological University (NTU) has invented a unique biomarker with two exceptional functions.
First, it lights up when it detects tumour cells to allow scientists to take a better look. And it can also release anti-cancer drugs at the same time to the specific cells.
This new biomarker, which has immense potential for drug development, is made from a nanophosphor particle, ten thousand times smaller than a grain of sand.
NTU associate professors Zhang Qichun and Joachim Loo have found a way to make the nanoparticle light up when it is activated by near-infrared light emitted by an imaging device and only if tumour cells release small signalling molecules.
Prof Zhang said the use of near-infrared light, which is invisible to the human eye, is unique as most imaging techniques use ultraviolet light or visible light.
“Near-infrared light can penetrate 3–4 cm beyond the skin to deep tissue, much deeper than visible light. It also does not cause any damage to healthy cells, unlike ultraviolet or visible light,” added Prof Zhang, a materials expert.
“Visible light also causes photo bleaching, which is the destruction of the fluorescence dye that reduces the amount of time doctors and scientists have to image a tissue sample. Our new biomarker has effectively eliminated such key limitations which exist in existing biological markers.”
The breakthrough has resulted in two papers published in Small — a scientific journal for material science and nanotechnology.
Prof Loo said their new biomarker can also release anti-cancer drugs by creating a layer of coating loaded with drugs on the outside of the nanoparticle. The drugs are released when the biomarker lights up in response to the near-infrared light.
“This is the first time we are able to do bio-imaging, and potentially target the delivery of drugs at the same time, as proven in small animal tests,” said Prof Loo, a nanotechnology and bioimaging expert. “Our breakthrough will open up new doors in the various fields of nanomedicine, bioimaging and cancer therapeutics.”
The new biomarker also has other advantages. It has twice the contrast of conventional dyes and is able to emit up to three different colours of light. This means that it allows for better differentiation between healthy cells and tumour cells.
Unlike other new biomarkers used for imaging such as quantum dots, the NTU biomarker has also been shown to be non-toxic, staying in the body for up to two days before it is passed out harmlessly.
The team from NTU’s School of Materials Science and Engineering will be looking to load multiple layers of drugs into their biomarker. If successful, doctors will be able to release sequentially two or more drugs through the biomarker. This will benefit cancer patients as there will be fewer side effects due to the small doses administered and also higher efficacy as the biomarker has the ability to accurately target tumour cells.
The project, which took 3 years, is jointly funded by NTU, the Ministry of Education and the National Research Foundation, Singapore.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance